News

Filter

Current filters:

OncoGenex

OncoGenex and Teva’s prostate cancer drug fails in Ph III study

29-04-2014

Israel’s Teva Pharmaceutical Industries and partner OncoGenex Pharmaceuticals released data from a…

custirsenOncoGenexOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

Teva and OncoGenex update on prostate cancer drug development; loss widens at latter

12-03-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) and US/Canadian partner OncoGenex Pharmaceuticals…

BiotechnologycustirsenFinancialLicensingOncoGenexPharmaceuticalResearchTeva Pharmaceutical Industries

US FDA delays Teva’s Neutroval BLA; custirsen enters second Ph III trial

04-10-2010

The US Food and Drug Administration has issued a Complete Response Letter for the Biologic License Application…

custirsenGenericsNeupogenNeutrovalOncoGenexOncologyPharmaceuticalRegulationResearchTeva Pharmaceutical Industries

Back to top